GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Trevena Inc (NAS:TRVN) » Definitions » Equity-to-Asset

Trevena (Trevena) Equity-to-Asset : -0.19 (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Trevena Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Trevena's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-7.66 Mil. Trevena's Total Assets for the quarter that ended in Dec. 2023 was $40.61 Mil. Therefore, Trevena's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was -0.19.

The historical rank and industry rank for Trevena's Equity-to-Asset or its related term are showing as below:

TRVN' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.19   Med: 0.66   Max: 0.92
Current: -0.19

During the past 13 years, the highest Equity to Asset Ratio of Trevena was 0.92. The lowest was -0.19. And the median was 0.66.

TRVN's Equity-to-Asset is ranked worse than
87.41% of 1565 companies
in the Biotechnology industry
Industry Median: 0.67 vs TRVN: -0.19

Trevena Equity-to-Asset Historical Data

The historical data trend for Trevena's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trevena Equity-to-Asset Chart

Trevena Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.64 0.82 0.81 0.32 -0.19

Trevena Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.32 0.27 0.25 0.08 -0.19

Competitive Comparison of Trevena's Equity-to-Asset

For the Biotechnology subindustry, Trevena's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Trevena's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Trevena's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Trevena's Equity-to-Asset falls into.



Trevena Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Trevena's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-7.657/40.605
=-0.19

Trevena's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-7.657/40.605
=-0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Trevena  (NAS:TRVN) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Trevena Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Trevena's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Trevena (Trevena) Business Description

Traded in Other Exchanges
Address
955 Chesterbrook Boulevard, Suite 110, Chesterbrook, PA, USA, 19087
Trevena Inc is an American biopharmaceutical company focused on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders.
Executives
Mark Corrigan director
Mark Demitrack officer: SVP, Chief Medical Officer 955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087
Robert T Yoder officer: SVP, Chief Business Officer 955 CHESTERBROOK BOULEVARD, SUITE 110, SUITE 200, CHESTERBROOK PA 19087
Carrie L. Bourdow director, officer: President & CEO C/O TREVENA, INC., 1018 WEST 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Patricia M. Drake officer: SVP, Chief Commercial Officer 245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Barry Shin officer: SVP, CFO C/O TREVENA, INC., 955 CHESTERBROOK BLVD, SUITE 110, CHESTERBROOK PA 19087
Marvin Johnson director C/O TREVENA, INC., 955 CHESTERBROOK BOULEVARD, STE. 110, CHESTERBROOK PA 19087
Barbara Yanni director 1018 W. 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Moulder Leon O Jr director C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Jason Raleigh Nunn director 1119 ST. PAUL STREET, BALTIMORE MD 21202
Scott Braunstein director C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Michael R Dougherty director C/O ADOLOR CORP, 700 PENNSYLVANIA DR, EXTON PA 19341
Anne M. Phillips director C/O TREVENA, INC., 1018 WEST 8TH AVENUE, KING OF PRUSSIA PA 19406
Scott Applebaum officer: CLCO; SVP, Regulatory Affairs C/O TREVENA INC., 955 CHESTERBROOK BOULEVARD, SUITE 110, CHESTERBROOK PA 19087
John P. Hamill officer: Int. Prin. Fin. Off. and PAO 4092 NEW HOPE ROAD, FURLONG PA 18925